Wedbush Decreases Earnings Estimates for Keros Therapeutics
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Equities research analysts at Wedbush cut their Q2 2025 earnings per share estimates for Keros Therapeutics in a report released on Wednesday, May 7th. Wedbush analyst Y. Zhong now expects that the company will post earnings of ($1.35) per share for the quarter, down from their prior […]
Keros Therapeutics, Inc. (NASDAQ:KROS – Free Report) – Equities research analysts at Wedbush cut their Q2 2025 earnings per share estimates for Keros Therapeutics in a report released on Wednesday, May 7th. Wedbush analyst Y. Zhong now expects that the company will post earnings of ($1.35) per share for the quarter, down from their prior […]
